collaboration

Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.

The companies will use ProSciento's Nash Pass patient registry and Nordic Bioscience's biomarker technology to validate the translational biomarkers.

The study's goal is to measure the success rate of SkylineDx's multiple myeloma test in a real-world setting compared to the hospital's current standard.

The partners aim to develop new diagnostic technologies and businesses, with a focus on diseases for which there are no established diagnostic methods.

Atrin will use Predictive's GenDB databases and women's health biobank to study germline mutations in DNA damage and response inhibitor pathways. 

FIND said that the consortium will evaluate the impact on clinical trial participants of innovative diagnostic technologies versus current standards of care.

The partners will extend the lung cancer biomarker study to countries in and outside Europe, and see if liquid biopsy could offer benefits to tissue-based testing.

The group aims to develop a transcriptomic and epigenetic biomarker assay for early detection and relapse monitoring in colorectal cancer patients. 

The researchers will use Agilent's Fourier-transform infrared spectroscopy technology to monitor infants and determine those at highest risk of developing atopic eczema.